These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9672231)

  • 21. In vitro selection of HIV and CMV specific T-lymphocytes.
    Li Pira G; Bottone L; Ivaldi F; Ricciardi A; Barbano G; Manca F
    J Biol Regul Homeost Agents; 2004; 18(2):183-6. PubMed ID: 15471225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TH1/TH2 switching and loss of CD4+ T cells in chronic infections: an immunoendocrinological hypothesis not exclusive to HIV.
    Rook GA; Onyebujoh P; Stanford JL
    Immunol Today; 1993 Nov; 14(11):568-9. PubMed ID: 7903855
    [No Abstract]   [Full Text] [Related]  

  • 23. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 24. Of mice and men: cytotoxic T cells and AIDS pathogenesis.
    Klenerman P; Zinkernagel RM
    AIDS Read; 1999 Oct; 9(7):474-80. PubMed ID: 12737139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunodominance of HIV-1-specific CD8(+) T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics.
    Lichterfeld M; Yu XG; Le Gall S; Altfeld M
    Trends Immunol; 2005 Mar; 26(3):166-71. PubMed ID: 15745859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
    Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
    Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
    [No Abstract]   [Full Text] [Related]  

  • 27. Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections.
    Ellefsen K; Harari A; Champagne P; Bart PA; Sékaly RP; Pantaleo G
    Eur J Immunol; 2002 Dec; 32(12):3756-64. PubMed ID: 12516570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
    Kumar A; Buch S; Foresman L; Bischofberger N; Lifson JD; Narayan O
    Virology; 2001 Jan; 279(1):97-108. PubMed ID: 11145893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of HIV-1-specific T-helper cells in acute and chronic infection.
    Rosenberg ES; LaRosa L; Flynn T; Robbins G; Walker BD
    Immunol Lett; 1999 Mar; 66(1-3):89-93. PubMed ID: 10203039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The interplay of herpesviruses in AIDS: superantigen sharing.
    Sutkowski N; Thorley-Lawson DA; Huber BT
    Trends Microbiol; 1996 Mar; 4(3):89-91. PubMed ID: 8868084
    [No Abstract]   [Full Text] [Related]  

  • 31. Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells.
    Zhan X; Slobod KS; Surman S; Brown SA; Coleclough C; Hurwitz JL
    Vaccine; 2004 Mar; 22(9-10):1206-13. PubMed ID: 15003649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of opportunistic infections on the frequency of leukocyte subpopulations from type-1 human immunodeficiency virus infected individuals].
    Ramírez Z; Cataño JC; Román A; Rugeles MT; Montoya CJ
    Biomedica; 2008 Mar; 28(1):64-77. PubMed ID: 18645662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intermittent therapy ought to strengthen the immune system].
    Volkert R
    Dtsch Med Wochenschr; 1999 Mar; 124(11):A8. PubMed ID: 10209528
    [No Abstract]   [Full Text] [Related]  

  • 34. Lung-specific immune response in tuberculosis.
    Condos R; Rom WN; Weiden M
    Int J Tuberc Lung Dis; 2000 Feb; 4(2 Suppl 1):S11-7. PubMed ID: 10688143
    [No Abstract]   [Full Text] [Related]  

  • 35. Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
    Weinberg A; Wohl DA; Barrett RJ; van der Horst C
    J Infect Dis; 2001 Sep; 184(6):707-12. PubMed ID: 11517431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new theory of cytotoxic T-lymphocyte memory: implications for HIV treatment.
    Wodarz D; Page KM; Arnaout RA; Thomsen AR; Lifson JD; Nowak MA
    Philos Trans R Soc Lond B Biol Sci; 2000 Mar; 355(1395):329-43. PubMed ID: 10794051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.
    McNeil AC; Shupert WL; Iyasere CA; Hallahan CW; Mican JA; Davey RT; Connors M
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13878-83. PubMed ID: 11717444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A brief history of HIV vaccine research: stepping back to the drawing board?
    Miedema F
    AIDS; 2008 Sep; 22(14):1699-703. PubMed ID: 18753857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human cytomegalovirus (HCMV)-specific CD4+ T lymphocyte response in AIDS patients with no past or current HCMV disease following HAART.
    Tamarit A; Alberola J; Mir A; Benet I; Mira JV; Muñoz C; Galindo MJ; Navarro D
    J Clin Virol; 2004 Apr; 29(4):308-14. PubMed ID: 15018860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The value of preserving HIV-specific immune responses.
    Kaufmann DE; Rosenberg ES
    J HIV Ther; 2003 Feb; 8(1):19-25. PubMed ID: 12840711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.